AndroGel Pregnancy and Lactation Safety

Why AndroGel Carries an Absolute Pregnancy Contraindication

Testosterone is a known teratogen. The FDA assigned Category X to all exogenous testosterone formulations, including AndroGel 1% and 1.62%, because the documented risk to a developing fetus outweighs any conceivable benefit in a pregnant individual. This is not a relative warning. It is a hard stop.

Mechanism of Fetal Harm

During embryonic development, androgens drive sexual differentiation of the external genitalia between gestational weeks 8 and 12. Exposure to exogenous testosterone during this window can cause virilization of female fetuses, including labioscrotal fusion, clitoromegaly, and ambiguous genitalia. Animal reproductive toxicology studies in rats and rabbits confirmed dose-dependent masculinization of female offspring when dams received testosterone during organogenesis 1.

The risk is not limited to that single window. Testosterone exposure at later gestational stages may affect neurological development, gonadal maturation, and endocrine programming. A 2019 systematic review published in the Journal of Clinical Endocrinology & Metabolism identified associations between prenatal androgen excess and altered metabolic programming in offspring followed through puberty 2.

Documented Human Case Data

Case reports in the medical literature describe virilization of female neonates after maternal testosterone exposure from compounded creams, pellets, and gels. One case series published in the Journal of Pediatric Endocrinology documented clitoromegaly and partial labial fusion in three female infants born to mothers who used testosterone cream in the first trimester before pregnancy recognition 3. Surgical correction was required in two of the three cases.

These cases underscore a practical clinical problem: topical testosterone formulations can transfer to partners through casual skin contact, creating inadvertent exposure even when the prescription belongs to a male partner.

The Secondary Transfer Problem

The FDA issued a boxed warning for AndroGel in 2009 specifically addressing secondary exposure through skin-to-skin contact. This warning followed post-marketing reports of virilization in children who contacted application sites on adult male users 4.

How Transfer Occurs

AndroGel is designed for transdermal absorption. The gel creates a testosterone reservoir in the stratum corneum that releases hormone over approximately 24 hours. Direct skin contact with the application site (shoulders, upper arms, abdomen) can transfer clinically meaningful amounts of testosterone to another person. The FDA's pharmacokinetic analysis found that an untreated female partner's serum testosterone could rise 2- to 3-fold above baseline after 15 minutes of direct skin contact with a treated application site 4.

Minimizing Transfer Risk

The prescribing information specifies five mandatory precautions:

1. Wash hands with soap and water immediately after application
2. Cover the application site with clothing once the gel has dried
3. Shower or wash the application site before any anticipated skin-to-skin contact
4. If a pregnant woman or child contacts the application site, that area should be washed with soap and water immediately
5. Apply to skin that will be covered by a T-shirt (shoulders, upper arms)

A pharmacokinetic study by Marbury et al. Demonstrated that washing the application site with soap and water reduced residual transferable testosterone by approximately 90% compared to unwashed skin 5. Clothing alone reduced transfer by roughly 50%.

Contraception Requirements for Partners of AndroGel Users

Any individual of childbearing potential who is a sexual partner or household contact of an AndroGel user must understand the dual risk: direct pharmacologic exposure through skin transfer and the (less discussed) possibility that a male partner on exogenous testosterone may still produce viable sperm.

Does Exogenous Testosterone Work as Male Contraception?

No. A common misconception holds that men on testosterone replacement therapy (TRT) are effectively infertile. While exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis and substantially reduces sperm production, it does not guarantee azoospermia.

The World Health Organization's multicenter contraceptive efficacy trial found that intramuscular testosterone enanthate 200 mg weekly induced azoospermia in only 65% of participants at 6 months, with the remaining 35% maintaining oligospermia (reduced but nonzero sperm counts) 6. Pregnancies have occurred in partners of men using TRT who assumed they were sterile.

Recommended Approach

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism states: "Testosterone therapy should not be initiated in men planning fertility in the near term," and recommends that clinicians discuss fertility preservation before starting TRT 7. For men currently on AndroGel whose partners may become pregnant:

• A reliable contraceptive method (barrier, hormonal, or IUD) should be used consistently
• Pregnancy should be excluded before any relaxation of transfer precautions
• If conception is desired, testosterone should be discontinued and spermatogenesis recovery monitored via serial semen analyses

Spermatogenesis Recovery After AndroGel Discontinuation

Exogenous testosterone suppresses gonadotropin-releasing hormone (GnRH), which in turn suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Without FSH stimulation, Sertoli cells cannot support normal spermatogenesis.

Recovery Timeline

A prospective study by Wenker et al. (2015) followed 66 men who discontinued TRT for fertility purposes. Median time to return of sperm in the ejaculate was 4.6 months, and 90% of men recovered sperm within 12 months 8. Duration of prior TRT use did not predict recovery time in multivariate analysis, though the study was not powered to detect differences beyond 3 years of use.

Adjunctive Recovery Protocols

Some clinicians prescribe clomiphene citrate (25 to 50 mg daily) or human chorionic gonadotropin (hCG, 1,500 to 3,000 IU two to three times weekly) to accelerate spermatogenesis recovery after TRT cessation. A retrospective analysis by Kohn et al. (2017) reported that men treated with clomiphene after TRT discontinuation achieved total motile sperm counts adequate for intrauterine insemination in a median of 4.1 months 9.

The American Urological Association (AUA) 2018 guideline on male infertility supports the off-label use of clomiphene or hCG for gonadotropin recovery in this setting 10.

AndroGel and Lactation

Testosterone is contraindicated during breastfeeding. This applies to direct use by the lactating individual and to secondary transfer from a partner using AndroGel.

Passage Into Breast Milk

Testosterone is a lipophilic steroid hormone with a molecular weight of 288.4 Da. It crosses biological membranes readily and is expected to pass into human breast milk based on physicochemical properties, though controlled pharmacokinetic studies in lactating women have not been conducted for ethical reasons. The National Library of Medicine's LactMed database classifies testosterone as "should be used with caution during breastfeeding" and notes that effects on the nursing infant are unknown but potentially concerning 11.

Risks to the Nursing Infant

Theoretical risks to a breastfed infant exposed to exogenous testosterone include:

• Premature virilization (accelerated bone age, precocious puberty signs)
• Disruption of the neonatal HPG axis, which is transiently active during the "mini-puberty" of infancy (first 6 months of life)
• Hepatotoxicity at high exposures (more relevant to oral formulations than gel transfer)

Practical Guidance for Households

When a male partner in the household uses AndroGel and the mother is breastfeeding:

• All secondary transfer precautions (handwashing, clothing barriers, showering before contact) must be followed rigorously
• The nursing infant should not contact the partner's application site
• Bed-sharing arrangements should account for potential overnight skin contact between the treated partner and the infant

How AndroGel Works: Mechanism and Pharmacokinetics

AndroGel delivers testosterone transdermally through a hydroalcoholic gel base. Understanding the pharmacokinetics matters for exposure risk assessment because it determines how long the application site remains a transfer hazard.

Absorption and Steady State

After application to clean, dry, intact skin, approximately 10% of the applied testosterone dose is absorbed systemically over 24 hours. The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with low testosterone, confirmed that daily application of 1% testosterone gel raised serum testosterone into the normal range (300 to 1,000 ng/dL) within 2 to 4 weeks 12.

Skin Depot Duration

After application and drying (which takes approximately 5 to 10 minutes), the gel leaves a testosterone reservoir in the skin that persists for hours. Pharmacokinetic sampling shows that serum testosterone peaks 2 to 8 hours after application and declines gradually, with approximately 40% to 60% of the depot still unabsorbed at 6 hours. This means the application site remains a meaningful transfer risk for at least 6 hours and a low-level risk for up to 10 hours post-application, even after the gel has dried.

Metabolism and Clearance

Once absorbed, testosterone undergoes hepatic first-pass metabolism via CYP3A4 and 5-alpha reductase to dihydrotestosterone (DHT) and aromatization via CYP19 to estradiol. The serum half-life of testosterone delivered transdermally is approximately 10 to 100 minutes, but the skin depot creates an effective sustained-release profile lasting roughly 24 hours.

Clinical Scenarios Requiring Extra Vigilance

Unplanned Pregnancy Discovery

If a partner of an AndroGel user discovers a pregnancy, the treating clinician should document the estimated date of conception relative to last known exposure. If direct skin transfer exposure occurred during the first trimester, referral to maternal-fetal medicine for detailed anatomic ultrasound at 18 to 20 weeks is recommended to assess fetal genital development.

Household With Young Children

The FDA's 2009 safety communication reported eight cases of secondary virilization in children (ages 9 months to 5 years) living in households with testosterone gel users. Signs included enlarged genitalia, advanced bone age, and aggressive behavior 4. All cases resolved after eliminating exposure.

IVF and Assisted Reproduction

Couples pursuing assisted reproduction face a timing challenge. The male partner must discontinue testosterone to recover spermatogenesis, but recovery takes months. Planning should begin at least 6 months before anticipated egg retrieval or IUI cycle. Sperm cryopreservation before initiating TRT remains the most reliable fertility preservation strategy 10.

When to Consult a Specialist

Referral to reproductive endocrinology or maternal-fetal medicine is warranted when:

• A pregnancy occurs in a partner of an AndroGel user with possible first-trimester exposure
• A couple wants to conceive and the male partner has been on TRT for more than 12 months
• Semen analysis shows persistent azoospermia more than 12 months after TRT cessation
• A breastfeeding infant develops signs of virilization (genital enlargement, acne, accelerated growth)

The Endocrine Society recommends baseline semen analysis before TRT initiation in any man who may desire future fertility 7.